- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04771026
The Effectiveness of Preemptive Nebulized Dexamethasone in Reducing Post-Operative Sore Throat in Supraglottic Airway (SGA)
The Effectiveness of Preemptive Nebulized Dexamethasone in Reducing Post- Operative Sore Throat Following the Use of AMBU® AURAGAINTM Device: A Double Blind, Randomised Clinical Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
The role of dexamethasone in reducing the incidence and severity of postoperative sore throat (POST) with ETT use is established in few studies. Some of the studies had done were found to have result on pertaining to efficacy of steroids in reducing incidences of POST in usage of SGA device, hence we decided to undertake this double-blinded, randomized study in patients undergoing general anaesthesia using the Ambu® AuraGainTM SGA device.
Dexamethasone which is 26.6 and 6.6 more potent than cortisol and prednisolone, acts via anti-inflammatory effects; inhibiting and reducing the release of inflammatory mediators. Hence this study aims to study the effectiveness of preoperative nebulized dexamethasone in reducing the incidence and severity of POST to improve patient satisfaction following general anaesthesia,and reduce morbidity.
OBJECTIVES
General:
To determine the effectiveness of preoperatively nebulized dexamethasone in reducing the incidence of post-operative sore throat following Ambu® AuraGainTM SGA device use.
Specific:
- To compare the incidence of post-operative sore throat (POST) with pre-operatively nebulized dexamethasone following insertion of Ambu® AuraGainTM SGA device at 30 minutes and 24 hours post operatively.
- To compare the severity of POST with pre-operatively nebulized dexamethasone using a visual analogue scale (VAS) following insertion of Ambu® AuraGainTM SGA device at 30 minutes and 24 hours post-operatively.
- To compare the incidence and severity of cough with pre-operatively nebulized dexamethasone using a 4-point scale grading at 30 minutes and 24 hours post-operatively following the insertion of Ambu® AuraGainTM SGA device.
- To compare the incidence and severity of hoarseness of voice with pre-operatively nebulized dexamethasone using a 4-point scale grading at 30 minutes and 24 hours post-operatively following the insertion of Ambu® AuraGainTM SGA device.
HYPOTHESIS
Null hypothesis H0:
There is no difference in terms of efficacy of pre-operatively nebulised dexamethasone in reducing the incidence and severity of POST Sore throat, cough and hoarseness will be graded as per Tazeh-Kand et al's study
Alternative hypothesis H1:
Pre-operatively nebulised dexamethasone is effective in reducing the incidence and severity of POST Sore throat, cough and hoarseness will be graded as per Tazeh-Kand et al's study
RESEARCH DESIGN The proposed study design is a single-centre, randomized, double-blind, controlled, parallel-group interventional study conducted in Kelantan, Malaysia.
Patients will be randomized (using a block randomization software) to 2 study arms (1:1 ratio), into Groups C and D whereby:
Group C: Control group, patients receiving usual standard of care in practice of SGA device (including analgesics), without receiving any active drug.
Group D: Patients receiving nebulised dexamethasone 8mg (2ml) with 3mls of normal saline 0.9% 30 minutes prior to induction of anaesthesia in the pre-operative receiving room via a wall-mounted oxygen source at 15L/minute.
After randomization, each patient will stay in their assigned treatment arm for the duration of the study.
This will be a double-blinded randomized controlled study, carried out by a single operator and assessor. Both operator/ assessor and patient will be blinded.
STUDY AREA Operating theatres in Hospital Universiti Sains Malaysia, HUSM, Kubang Kerian.
INTERVENTIONS Group C: Control group, patients receiving usual standard of care in practice of SGA device (including analgesics), without receiving any active drug.
Group D: Patients receiving nebulised dexamethasone 8mg (2ml) with 3mls of normal saline 0.9% 30 minutes prior to induction of anaesthesia in the pre-operative receiving room via a wall-mounted oxygen source at 15L/minute.
SAMPLE SIZE ESTIMATION The sample size was estimated using the PS Software version 3.1.2 (Dupont and Plummer 1997) based on comparing 2 proportions for incidence of sore throat, And G*Power version 3.1.9.4 (Erdfelder, Faul, & Buchner, 1996) based on a 3 point scale for determining the severity of sore throat, cough and hoarseness of voice.
Where:
- Alpha: 0.05
- Power: 80%
Based on the parameters in the study by Tazeh-Kand NF, Eslami B, Mohammadian K. Inhaled fluticasone propionate reduces postoperative sore throat, cough, and hoarseness. Anesth Analg. 2010 Oct;111(4):895-8 (23).
The largest sample size generated was 128 (for 64 patients in each arm) for incidence of cough 1 hour post-operatively to detect a 30% difference in prevalence of cough between 2 study groups with a alpha value of 0.05 and power of 80%.
DATA COLLECTION METHOD After written consent pre-operatively, patients will be randomized as 2 groups
- Group C, and Group D. Group C: Patients receiving normal conduct of anaesthesia Group D: Patients receiving dexamethasone 8mg (2ml) with 3mls of normal saline 0.9%.
Patients will receive a sealed, opaque envelope containing a code with either N or D according to the randomization software pre-operatively, which will be opened by an anesthesiologist or nurse not involved in the study. The anesthesiologist or nurse opening the envelope will be told to withhold this information from the operator/investigator and patient. If the envelope contains the letter D, the said nurse/ anesthesiologist will be told to prepare and administer the nebulised drug as described, also without the knowledge of the operator/investigator. The operator/investigator will have no contact with the patient once the envelope is opened, and will remain away from the preoperative receiving room for 30 minutes from the arrival of patient.
Patients in group D will receive a total of 5mls of nebulized drug 30 minutes prior to induction of anaesthesia in the pre-operative receiving room via a wall-mounted oxygen source at 15L/minute.
After nebulisation for 30 minutes in the pre-operative receiving area, patients will be brought to the respective operating theatre. Monitoring according to standards will be applied - Non-invasive blood pressure, ECG, oxygen saturation, and capnography.
A humidified gas exchanger will be used for all patients.
Conduct of anesthesia will be as follows:
- Patients will not be premedicated
- Patients will be pre-oxygenated with 100% oxygen for 3-5 minutes or until an end-tidal oxygen fraction of 85 is achieved
- Intravenous induction with IV Fentanyl 1-2 mcg/kg, IV Propofol 1-3mg/kg, with no use of neuromuscular blockade of IV Dexamethasone.
- The insertion of a fully deflated SGA AMBU AURAGAIN® lubricated with Lignocaine 2% on the posterior aspect using the appropriate size according to patients' weight once there is loss of eyelash reflex by the operator using a standardized technique. The cuff will then be inflated with appropriate amount of air according to LMA size
- Cuff pressure will be measured immediately once the airway is secured, and subsequently measured hourly using a handheld pressure gauge. Cuff pressure of not more than 60 cmH20 will be maintained
- Anaesthesia will be maintained using Sevoflurane, titrated to a Minimum Alveolar Concentration (MAC) of 0.9-1.0 in 50/50 oxygen/air mixture with SIMV (Pressure or volume control) mode
- At the end of anaesthesia, the oral airway will be suctioned once gently and 100% oxygen will be administered until the SGA removed without deflation once regular, spontaneous ventilation has returned with opening of eyes to calling of name
Patients will be transferred to the recovery area where all patient will receive supplemental oxygen via face mask at 5L/minute until discharged from the post-operative recovery unit.
The 4 point questionnaire on POST will be applied at 30 minutes to 1 hour and 24 hours post-operatively in the ward by the same operator. If the patient is discharged prior to the 24 hour interview, they will be followed up via phone.
Scoring System for Sore Throat, Cough and Hoarseness, from Tazeh-kand et al:
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: rhendra hardy Mohamad zaini, MD
- Phone Number: 6095 +60199106665
- Email: rhendra@gmail.com
Study Contact Backup
- Name: Christy Anne Lee, MBBS
- Phone Number: 6095 09 767 3000
- Email: 87christyanne@gmail.com
Study Locations
-
-
Kelantan
-
Kubang Kerian, Kelantan, Malaysia, 16150
- University of Science Malaysia Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Between the ages of 18-70 years
- American Society of Anaesthesiology (ASA) physical status of 1 and 2
- Patients undergoing elective procedures under general anaesthesia between the data collection period suitable for SGA device
Exclusion Criteria:
- Pre-existing sore throat/hoarseness on pre-operative assessment
- Patients with history of postoperative nausea or vomiting
- Recent (2 weeks) upper or lower respiratory tract infection
- Known hypersensitivity to dexamethasone or on regular steroids
- Uncontrolled diabetes of capillary blood sugar more than 10mmol/l on pre-operative assessment
- Morbidly obese with BMI > 40 kg/m2
- Procedure exceeding 3 hours duration
- Procedure requiring prone or Trendelenburg position or manipulation of head post-induction
- Oral and neck surgeries
- Pregnant patients
- Patients with cognitive disabilities
- Patients requiring nasogastric tube or nasal temperature probe insertion
- Patient refusal
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control
Receiving routine conduct of general anaesthesia for supraglottic airway device
|
|
Experimental: Dexamethasone
Receiving pre-operatively single dose nebulised dexamethasone 8mg prior to induction of general anaesthesia
|
Pre-operatively nebuliser dexamethasone 8mg prior to induction of anesthesia
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of POST up to 24 hours post-operatively in patients who received pre-operative nebulized dexamethasone
Time Frame: up to 24 hours post-operatively
|
Patients will be evaluated using scoring system for sore throat, cough and hoarseness
|
up to 24 hours post-operatively
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of cough up to 24 hours post-operatively in patients who received pre-operative nebulized dexamethasone
Time Frame: up to 24 hours post-operatively
|
Patients will be evaluated using scoring system for sore throat, cough and hoarseness
|
up to 24 hours post-operatively
|
Incidence of hoarseness of voice up to 24 hours post-operatively in patients who received pre-operative nebulized dexamethasone
Time Frame: up to 24 hours post-operatively
|
Patients will be evaluated using scoring system for sore throat, cough and hoarseness
|
up to 24 hours post-operatively
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: rhendra hardy Mohamad Zaini, MD, Universiti Sains Malaysia
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Respiration Disorders
- Neurologic Manifestations
- Pharyngeal Diseases
- Stomatognathic Diseases
- Otorhinolaryngologic Diseases
- Signs and Symptoms, Respiratory
- Laryngeal Diseases
- Voice Disorders
- Pharyngitis
- Dysphonia
- Hoarseness
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Dexamethasone
Other Study ID Numbers
- USM/JEPeM/19120934
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hoarseness
-
University of UtahNational Institute on Deafness and Other Communication Disorders (NIDCD)SuspendedVoice Disorders | Voice Hoarseness | Voice FatigueUnited States
-
Université de MontréalMaisonneuve-Rosemont HospitalCompletedApnea | Cough | Desaturation | Laryngospasm | Voice HoarsenessCanada
-
Seth Gordhandas Sunderdas Medical CollegeCompleted
-
Chonnam National University HospitalCompletedThyroidectomy | Sore Throat | Voice HoarsenessKorea, Republic of
-
B.P. Koirala Institute of Health SciencesCompletedPostoperative Sore Throat, Cough, HoarsenessNepal
-
University of Kansas Medical CenterTAP Pharmaceutical Products Inc.Terminated
-
University of MinnesotaNational Institute on Deafness and Other Communication Disorders (NIDCD)RecruitingDysphonia | Voice Disorders | Functional DysphoniaUnited States
-
Prof. Dr. Cemil Tascıoglu Education and Research...Completed
-
Hacettepe UniversityRecruiting
-
Seoul National University HospitalCompletedHoarsenessKorea, Republic of
Clinical Trials on Dexamethasone
-
Ottawa Hospital Research InstituteCompletedPain Syndrome | Early-stage Breast CancerCanada
-
Centre hospitalier de l'Université de Montréal...CompletedPrevention of Hypersensitivity Reactions to PaclitaxelCanada
-
Shanghai Jiao Tong University Affiliated Sixth...CompletedAnalgesia | Time | Brachial Plexus Block | Shoulder Surgery | Dexamethasone | Intravenous Drug UsageChina
-
Universidade Federal de PernambucoCompletedDiabetic Macular EdemaBrazil
-
Vanderbilt University Medical CenterTerminatedAsthma | CroupUnited States
-
Dr. Stephen ChoiThe Physicians' Services Incorporated FoundationCompletedShoulder Surgery | Nerve BlockCanada
-
Universitätsklinikum Hamburg-EppendorfGemeinsamer Bundesausschuss (G-BA); Staburo GmbHRecruiting
-
Poznan University of Medical SciencesRecruitingWrist Injuries | Hand Injuries | Hand Injuries and Disorders | Hand Disease | Wrist DiseasePoland
-
University of California, San FranciscoCompletedOral Lichen Planus | Pemphigus Vulgaris | Mucous Membrane Pemphigoid | Chronic Graft-versus-host-diseaseUnited States
-
University of BelgradeCompleted